Спазм коронарных артерий: механизмы развития и возможности его коррекции

Шевченко Ю.Л., Гудымович В.Г., Мирзахамдамов Ж.М.

Представлен обзор современных и ретроспективных тенденций в лечении пациентов со спазмом коронарных артерий при ЧКВ и открытых операций на сердце. Применяемые лечебно-диагностические алгоритмы не всегда позволяют решить вопрос о спазме коронарных артерий. Поиск путей уменьшения частоты спазма коронарных артерий является приоритетной задачей. В обзоре рассматриваются частота и факторы развития спазма коронарных артерий, применяемые методы профилактики и лечения.

1. Огрызко Е.В., Иванова М.А., Одинец А.В. и др. Динамика заболеваемости взрослого населения острыми формами ишемической болезни сердца и смертности от них в Российской Федерации в 2012–2017 гг. // Профилактическая медицина. — 2019. — №22(5). — С.23-26.

2. Soejima H, Irie A, Miyamoto S, Kajiwara I, et al. Preference toward a T-helper type 1 response in patients with coronary spastic angina. Circulation. 2003; 107: 2196-2200.

3. Okumura K, Yasue H, Horio Y, et al. coronary spasm in patients with variant angina: a study with intracoronary injection of acetylcholine. Circulation. 1988; 77: 535-542.

4. Пономаренко И.В., Сукманов И.А. Клинико-гемодинамические характеристики пациентов с острым коронарным синдромом молодого возраста // Комплексные проблемы сердечно-сосудистых заболеваний. — 2018. — №1. — С.14-20.

5. Beijk MA, Vlastra WV, Delewi R, van de Hoef TP, Boekholdt SM, Sjauw KD, Piek JJ. Myocardial infarction with non-obstructive coronary arteries: a focus on vasospastic angina. Neth Heart J. 2019; 27(5): 237-245.

6. Picard F, Sayah N, Spagnoli V, et al. Vasospastic angina: A literature review of current evidence. Arch Cardiovasc Dis. 2019; 112(1): 44-55. doi: 10.1016/j.acvd.2018.08.002.

7. Matta A, Bouisset F, Lhermusier T, et al. Coronary artery spasm: new insights. J Interv Cardiol. 2020; 2020: 5894586.

8. Sato K, Kaikita K, Nakayama N, et al. Coronary Vasomotor Response to Intracoronary Acetylcholine Injection, Clinical Features, and Long- term Prognosis in 873 Consecutive Patients With Coronary Spasm: Analysis of a Single-Center Study Over 20 Years. J Am Heart Assoc. 2013; 2(4): e000227.

9. Takagi Y, Yasuda S, Tsunoda R, еt al. Clinical characteristics and long- term prognosis of vasospastic angina patients who survived out- of- hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011; 4: 295-302.

10. Ogawa H, Akasaka T, Hattori R, et al. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. Circ J. 2010; 74: 1745-1762.

11. Moltrasio M, Cosentino N, Conte E, et al. Treatment of refractory vasospastic angina complicated by acute pulmonary oedema with levosimendan: a case report. Eur Heart J Case Rep. 2019; 3(1): ytz002. doi: 10.1093/ehjcr/ytz002.

12. Yasue H, Mizuno Y, Harada E. Coronary artery spasm — clinical features, pathogenesis and treatment. Proc Jpn Acad Ser B Phys Biol Sci. 2019; 95(2): 53-66.

13. Gaetano Antonio Lanza, Giulia Careri, Filippo Crea Mechanisms of Coronary Artery Spasm. Circulation. 2011; 124: 1774-1782. doi: 10.1161/ CIRCULATIONAHA.111.037283.

14. Шевченко Ю.Л., Ермаков Д.Ю. Электрокардиография из венечного синуса. М.: Национальный медико-хирургический Центр им. Н.И.Пирогова, 2022. — 136 с.

15. Hung MJ, Cherng WJ, Yang NI, Cheng CW, Li LF. Relation of high- sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. Am J Cardiol. 2005; 96: 1484-1490.

16. Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018; 138(2): 131-140. doi: 10.1161/CIRCULATIONAHA.118.034032.

17. Nedeljkovic MA, Ostojic MC, Beleslin BD, et al. Ergonovine-induced changes of coronary artery diameter in patients with nonsignificant coronary artery stenosis : relation with lipid profile. Herz. 2007; 32(4): 329-35.

18. Singh A, Arya RС, Mohan B. Milrinone infusion: a therapeutic option in coronary vasospasm after primary percutaneous transluminal coronary angioplasty. Ann Card Anaesth .2009; 12(1): 67-70. doi: 10.4103/0971-9784.45017.

19. Takei Y, Mori H, Sone H, Tashiro K, Sasai M, Sato T, Suzuki H. Polygon-like luminal configuration captured by intracoronary optical frequency domain imaging of a spontaneous coronary spasm in an ST-elevation myocardial infarction patient. Coron Artery Dis. 2019; 30(4): 314-315. doi: 10.1097/MCA.0000000000000728.

20. Yunpeng B, Yiming B, Nan J, et al. Perioperative coronary artery spasm after off-pump coronary artery bypass grafting in the non-manipulated coronary artery. BMC Cardiovascular Disorders. 22; 166(2022).

21. Carneiro JD, Lima JA, Simões RM, Stolf NA. Coronary-artery spasm after coronary artery bypass graft surgery without extracorporeal circulation: diagnostic and management. Rev Bras Cir Cardiovasc. 2010; 25(3): 410-4.

22. He GW, Taggart DP. Spasm in arterial grafts in coronary artery bypass grafting surgery. Ann Thorac Surg. 2016; 101(3): 1222-9.

23. Spirito A, Gragnano F, Corpataux N, et al. Sex-based differences in bleeding risk after percutaneous coronary intervention and implications for the academic research consortiusawam high bleeding risk criteria. J Am Heart Assoc. 2021; 10(12): e021965.

24. Mehta PK, Thobani A, Vaccarino V. Coronary artery spasm, coronary reactivity, and their psychological context. Psychosom Med. 2019; 81(3): 233-6.

25. Митьковская Н.П., Ласкина О.В., Тифи П. Нестабильная стенокардия или нестабильные коронарные синдромы? // Неотложная кардиология и кардиоваскулярные риски. — 2020. — Т.4. — №1. — С.816-849.

26. Beltrame JF, Crea F, Kaski JC, еt al. The who, what, why, when, how and where of vasospastic angina. Circ J. 2016; 80: 289-298.

27. Ong P, Athanasiadis A, Hill S, еt al. Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome). Study. J Am Coll Cardiol. 2008; 52: 523-527.

28. Jae YP, Eun-Ju K, Moo HK, et al. Assessment of coronary spasms with transluminal attenuation gradient in coronary computed tomography angiography. PLoS One. 2022; 17(7): e0271189. doi: 10.1371/journal.pone.0271189.

29. Inobe Y, Kugiyama K, Morita E, et al. Role of adenosine in pathogenesis of syndrome X: assessment with coronary hemodynamic measurements and thallium- 201 myocardial.

30. Sueda S, Kohno H, Fukuda H, Ochi N, Kawada H, Hayashi Y, Uraoka T. Induction of coronary artery spasm by two pharmacological agents: comparison between intracoronary injection of acetylcholine and ergonovine. Coron Artery Dis. 2003; 14: 451-457.

31. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014; 78(11): 2779-801. doi: 10.1253/circj.cj-66-0098.

32. Шевченко Ю.Л., Карпов О.Э. Стентовая хирургия / Под ред. Ю.Л.Шевченко, О.Э.Карпова. — М.: ДПК Пресс, 2020. — 368 с.

33. Shozo S, Hiroaki K, Takaaki O, et al. Overview of the pharmacological spasm provocation test: Comparisons between acetylcholine and ergonovine. J Cardiol. 2017; 69(1): 57-65. doi: 10.1016/j.jjcc.2016.09.012.

34. Еременко А.А., Рыбка М.М. Противоишемические и кардиопротекторные эффекты левосимендана // Вестник интенсивной терапии. — 2016. — 4. — 27-33.

35. Nieminen MS, Buerke M, Cohen-Solál A, et al. The role of levosimendan in acute heart failure complicating coronary syndrome: a review and expert consensus opinion. Int J Cardiol. 2016; 218: 150-157.

36. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton A, de Belder MA. Heart. 2006; 92(9): 1278-84. doi: 10.1136/hrt.2005.075077.

37. Niccoli G, Rigattieri S, De Vita MR, et al. Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction: The REOPEN-AMI Study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC: Cardiovascular Interventions. 2013; 6(6): 580-589. doi: 10.1016/j.jcin.2013.02.009.

38. Grygier M, Araszkiewicz A, Lesiak M, Grajek S. Effect of New Method of Intracoronary Adenosine Injection during Primary Percutaneous Coronary Intervention.

39. Hamza M, Elgendy I. Intracoronary eptifibatide with vasodilators to prevent no-reflow in diabetic STEMI with high thrombus burden. A randomized trial. Rev Esp Cardiol. 2021; 75(9): 701-776. doi: 10.1016/j.rec.2021.10.012.

40. Huang X, Zheng W, Zhao XD, et al. CHA2DS2-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention. Medicine (Baltimore). 2021; 100(21): e26162.

41. Caiazzo G, Musci RL, Frediani L, et al. State of the Art: No-Reflow Phenomenon. Cardiol Clin. 2020; 38(4): 563-573.

42. Rezkalla SH, Stankowski RV, Hanna J, et al. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv. 2017; 10(3): 215-223.

43. Marinov V, Karanovic N, Carev M, et al. Intracoronary administration of levosimendan in patients with acute coronary syndromes and decreased left ventricular ejection fraction undergoing coronary artery bypass graft surgery. Signa Vitae. 2017; 13(2): 25-28.

44. Петросян К.В. Мультидисциплинарный подход в формате Heart Team — вектор оптимизации лечения пациентов с поражениями коронарного русла // Грудная и сердечно-сосудистая хирургия. — 2018. — Т.60. — №4. — С.287-293. doi: 10.24022/0236-2791-2018-60-4-287-293.

45. Eun ML, Man HC, Hong SS, et al. Impact of vasomotion type on prognosis of coronary artery spasm induced by acetylcholine provocation test of left coronary artery. Atherosclerosis. 2017; 257: 195-200. doi: 10.1016/j.atherosclerosis.2016.09.015.

46. Holmes DR, Rich JB, Zoghbi WA, Mack MJ. The heart team of cardiovascular care. J. Am. Coll. Cardiol. 2013; 61(9): 903-7. doi:1016/j.jacc. 2012.08.1034.